Skip to main content
SpringerLink
Log in

Ticagrelor not linked with lower MACE risk in patients with ACS

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. PLATO = Platelet Inhibition and Patient Outcomes

  2. including prior myocardial infarction, cerebrovascular disease, peripheral vascular disease, heart failure.

Reference

  • Turgeon RD, et al. Association of Ticagrelor vs Clopidogrel With Major Adverse Coronary Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA Internal Medicine : [18 pages], 13 Jan 2020. Available from: URL: http://doi.org/10.1001/jamainternmed.2019.6447

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ticagrelor not linked with lower MACE risk in patients with ACS. Reactions Weekly 1788, 12 (2020). https://doi.org/10.1007/s40278-020-74135-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-020-74135-8

Search

Navigation